09:53 AM EST - iCo Therapeutics Inc. : Announced that the company has engaged Corealis Pharma Inc., a contract manufacturing organization, for analytical development, formulation optimization and scale-up of the amphotericin B oral delivery system. The preparation and regulatory filings for this program are expected to be completed in 2016, with Phase 1A study data available in 2017. iCo Therapeutics Inc.
shares V.ICO are trading unchanged at $0.07.
